A review on control and fault-tolerant control systems of AC/DC microgrids.

Microgrids (MG) treat local energy supply issues effectively and from a point of view of the distribution grid, may be a power supply or virtual load. Despite holding a myriad of benefits, MGs also bear a set of challenges, including a higher fault rate. Currently, many articles focus on control techniques; however, little has been written about the techniques of control, hierarchical control, and fault-tolerant control (FTC) applied to MGs, which is the motive of this bibliographic revision on control systems. A brief comparison of the different approaches in the field of present-day research is carried out primarily addressing hierarchical control and fault tolerance. The objective of this investigation is to attract the interest of researchers to the field of control and fault tolerance applied to MGs, such as: modeling, testbed, benchmark systems, control and hierarchical control strategies, fault diagnosis and FTC.

Hybrid AC/DC microgrid test system simulation: grid-connected mode.

In this paper, a Microgrid (MG) test model based on the 14-busbar IEEE distribution system is proposed. This model can constitute an important research tool for the analysis of electrical grids in its transition to Smart Grids (SG). The benchmark is used as a base case for power flow analysis and quality variables related with SG and holds distributed resources. The proposed MG consists of DC and AC buses with different types of loads and distributed generation at two voltage levels. A complete model of this MG has been simulated using the MATLAB/Simulink environmental simulation platform. The proposed electrical system will provide a base case for other studies such as: reactive power compensation, stability and inertia analysis, reliability, demand response studies, hierarchical control, fault tolerant control, optimization and energy storage strategies.

Microbial Culturomics Application for Global Health: Noncontiguous Finished Genome Sequence and Description of Pseudomonas massiliensis Strain CB-1T sp. nov. in Brazil.

Culturomics is a new postgenomics field that explores the microbial diversity of the human gut coupled with taxono-genomic strategy. Culturomics, and the microbiome science more generally, are anticipated to transform global health diagnostics and inform the ways in which gut microbial diversity contributes to human health and disease, and by extension, to personalized medicine. Using culturomics, we report in this study the description of strain CB1T ( = CSUR P1334 = DSM 29075), a new species isolated from a stool specimen from a 37-year-old Brazilian woman. This description includes phenotypic characteristics and complete genome sequence and annotation. Strain CB1T is a gram-negative aerobic and motile bacillus, exhibits neither catalase nor oxidase activities, and presents a 98.3% 16S rRNA sequence similarity with Pseudomonas putida. The 4,723,534 bp long genome contains 4239 protein-coding genes and 74 RNA genes, including 15 rRNA genes (5 16S rRNA, 4 23S rRNA, and 6 5S rRNA) and 59 tRNA genes. Strain CB1T was named Pseudomonas massiliensis sp. nov. and classified into the family Pseudomonadaceae. This study demonstrates the usefulness of microbial culturomics in exploration of human microbiota in diverse geographies and offers new promise for incorporating new omics technologies for innovation in diagnostic medicine and global health.

Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.

A long-standing question and dilemma in precision medicine is whether and to what extent genotyping or phenotyping drug metabolizing enzymes such as CYP2D6 can be used in real-life global clinical and societal settings. Although in an ideal world using both genotype and phenotype biomarkers are desirable, this is not always feasible for economic and practical reasons. Moreover, an additional barrier for clinical implementation of precision medicine is the lack of correlation between genotype and phenotype, considering that most of the current methods include only genotyping. Thus, the present study evaluated, using dextromethorphan as a phenotyping probe, the relationship between CYP2D6 phenotype and CYP2D6 genotype, especially for the ultrarapid metabolizer (UM) phenotype. We report in this study, to the best of our knowledge, the first comparative clinical pharmacogenomics study in a Cuban population sample (N = 174 healthy volunteers) and show that the CYP2D6 genotype is not a robust predictor of the CYP2D6 ultrarapid metabolizer (mUM) status in Cubans. Importantly, the ultrarapid CYP2D6 phenotype can result in a host of health outcomes, such as drug resistance associated with subtherapeutic drug concentrations, overexposure to active drug metabolites, and altered sensitivity to certain human diseases by virtue of altered metabolism of endogenous substrates of CYP2D6. Hence, phenotyping tests for CYP2D6 UMs appear to be a particular necessity for precision medicine in the Cuban population. Finally, in consideration of ethical and inclusive representation in global science, we recommend further precision medicine biomarker research and funding in support of neglected or understudied populations worldwide.